{"id":296213,"date":"2024-05-21T00:00:00","date_gmt":"2024-05-21T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0005-2024-biopharma-rheumatoid-arthritis-access-reimbursement-access-and-reimbursement\/"},"modified":"2026-03-31T10:30:04","modified_gmt":"2026-03-31T10:30:04","slug":"acreim0005-2024-biopharma-rheumatoid-arthritis-access-reimbursement-access-and-reimbursement-rheumatoid-arthritis-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0005-2024-biopharma-rheumatoid-arthritis-access-reimbursement-access-and-reimbursement-rheumatoid-arthritis-us\/","title":{"rendered":"Rheumatoid Arthritis &#8211; Access &#038; Reimbursement &#8211; Access and Reimbursement &#8211; Rheumatoid Arthritis (US)"},"content":{"rendered":"<p>The availability of multiple targeted therapies with diverse mechanisms of action, including biologics \/ biosimilars and oral agents, along with conventional treatments, makes the rheumatoid arthritis (<abbr title=\"rheumatoid arthritis\">RA<\/abbr>) market increasingly crowded. The expected launch of R-Pharm\u2019s <abbr title=\"interleukin\">IL<\/abbr>-6 inhibitor olokizumab, will further fragment the market. Drug developers will undoubtedly face increasing challenges in gaining favorable formulary positioning and physician uptake. In such scenarios, market access decisions for these therapies will play a key role in influencing rheumatologists\u2019 prescribing behaviors in <abbr title=\"rheumatoid arthritis\">RA<\/abbr>. This report provides valuable insights into how payer coverage policies influence rheumatologists\u2019 prescribing decisions, helping marketers navigate this challenging market access environment.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How does the coverage of therapies for <abbr title=\"rheumatoid arthritis\">RA<\/abbr> differ on <abbr title=\"managed care organization\">MCO<\/abbr>s\u2019 largest commercial insurance plans? How do various cost-control measures impact the prescribing of current therapies for <abbr title=\"rheumatoid arthritis\">RA<\/abbr>?<\/li>\n<li>How do pharmacoeconomic \/ health economic outcomes data impact formulary decision making for therapies for <abbr title=\"rheumatoid arthritis\">RA<\/abbr>?<\/li>\n<li>What points of differentiation are \/ will be the most compelling to rheumatologists and payers of new therapies for <abbr title=\"rheumatoid arthritis\">RA<\/abbr>?<\/li>\n<li>Do physicians expect to prescribe key emerging therapy, olokizumab, to their <abbr title=\"rheumatoid arthritis\">RA<\/abbr> patients? How do payers intend to reimburse olokizumab, and how will those decisions affect prescribing?<\/li>\n<\/ul>\n<p><strong>Content highlights<\/strong><\/p>\n<p>Geography: United States.<\/p>\n<p>Primary research: Survey of 100 U.S. rheumatologists and 30 U.S. managed care organization (<abbr title=\"managed care organization\">MCO<\/abbr>) pharmacy and medical directors (<abbr title=\"pharmacy director\">PD<\/abbr>s\/<abbr title=\"medical director\">MD<\/abbr>s).<\/p>\n<p>Key drugs covered: Enbrel, Humira, adalimumab biosimilars, Remicade,\u00a0Orencia, Rituxan, Actemra, Kevzara, Xeljanz, Rinvoq, olokizumab<\/p>\n<p>Reimbursement and contracting.<\/p>\n<p>Access and prescribing.<\/p>\n<p>Special topics.<\/p>\n<p>Opportunities and challenges for emerging therapies.<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p><em>U.S. Access &#038; Reimbursement<\/em> provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.<\/p>\n","protected":false},"template":"","class_list":["post-296213","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatoid-arthritis","biopharma-therapy-areas-rheumatology","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296213","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296213\/revisions"}],"predecessor-version":[{"id":575964,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296213\/revisions\/575964"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296213"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}